A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

Denise A. YardleySarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Michael McCleodSarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Fred SchreiberSarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Patrick MurphySarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Jeffrey PattonSarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Dana S. ThompsonSarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Mythili ShastrySarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Mark RubinSarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Marianne MelnikSarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

Howard A. BurrisSarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

John D. HainsworthSarah Cannon Research Institute, Nashville, Tennesee, USA, Tennessee Oncology, PLLC, Nashville, Tennesee, USA, Florida Cancer Specialists, Fort Myers, Florida, USA, Watson Clinic, Lakeland, Florida, USA, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, USA

show all

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date